Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Más filtros











Intervalo de año de publicación
1.
Toxicol Lett ; 319: 175-186, 2020 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-31733319

RESUMEN

Information on the effects of gibberellic acid (gibberellin A3, GA3) on ovarian follicle development is limited. In our present study, 21-day-old female Wistar rats were exposed to GA3 by gavage (25, 50, and 100 mg/kg body weight, once per day) for eight weeks to evaluate the influence of GA3 on ovarian follicle development. After treatment, significant (P < 0.05) increases (to 40.17 % and 44.5 %, respectively) in atretic follicle proportions and significant decreases (to 19.49 % and 17.86 %, respectively) in corpus luteum proportions were observed in the 50 and 100 mg/kg treatment groups compared to the control group. Significant (P < 0.05) increases (to 31.3 % and 42.0 %, respectively) in follicle apoptosis were observed in the 50 and 100 mg/kg treatment groups by transmission electron microscopy and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assays. Significantly increased expression of caspase-3, caspase-8, caspase-9 and Fas was observed by real-time PCR and Western blotting. Bisulfite sequencing PCR (BSP) revealed obviously decreased total methylation percentages of the caspase-3 promoter region in the two treatment groups. Real-time quantitative PCR also showed significantly decreased mRNA expression of DNA methyltransferase (Dnmt) 3a and Dnmt3b. Further in vitro studies showed that a DNA methylation inhibitor could enhance the GA3-induced increase in the mRNA expression of caspase-3. Overall, our present study indicates that GA3 administration from weaning until sexual maturity can affect ovarian follicle development by inducing apoptosis and suggests that signaling through the Fas-mediated apoptotic pathway may be an important underlying mechanism of this apoptosis. In addition, GA3-induced aberrant DNA methylation patterns might be partly responsible for upregulation of caspase-3 gene expression.


Asunto(s)
Apoptosis/efectos de los fármacos , Caspasa 3/efectos de los fármacos , Metilación de ADN/efectos de los fármacos , Proteína de Dominio de Muerte Asociada a Fas/biosíntesis , Giberelinas/toxicidad , Células de la Granulosa/efectos de los fármacos , Ovario/citología , Transducción de Señal/efectos de los fármacos , Animales , ADN (Citosina-5-)-Metiltransferasas/biosíntesis , ADN (Citosina-5-)-Metiltransferasas/genética , ADN Metiltransferasa 3A , Proteína de Dominio de Muerte Asociada a Fas/efectos de los fármacos , Femenino , Folículo Ovárico/efectos de los fármacos , Ovario/efectos de los fármacos , Regiones Promotoras Genéticas/efectos de los fármacos , Ratas , Ratas Wistar , Superovulación/efectos de los fármacos , ADN Metiltransferasa 3B
2.
Braz J Med Biol Res ; 52(11): e8772, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31664306

RESUMEN

This study aimed to investigate the mechanism of fluorofenidone (AKF-PD) in treating renal interstitial fibrosis in rats with unilateral urinary obstruction (UUO). Thirty-two male Sprague-Dawley rats were randomly divided into sham, UUO, UUO + enalapril, and UUO + AKF-PD groups. All rats, except sham, underwent left urethral obstruction surgery to establish the animal model. Rats were sacrificed 14 days after surgery, and serum was collected for renal function examination. Kidneys were collected to observe pathological changes. Immunohistochemistry was performed to assess collagen I (Col I) protein expression, and terminal deoxynucleotidyl transferase-mediated nick end-labeling staining to observe the apoptosis of renal tubular epithelial cells. The expression of Fas-associated death domain (FADD), apoptotic protease activating factor-1 (Apaf-1), and C/EBP homologous protein (CHOP) proteins was evaluated by immunohistochemistry and western blot analysis. AKF-PD showed no significant effect on renal function in UUO rats. The pathological changes were alleviated significantly after enalapril or AKF-PD treatment, but with no significant differences between the two groups. Col I protein was overexpressed in the UUO group, which was inhibited by both enalapril and AKF-PD. The number of apoptotic renal tubular epithelial cells was much higher in the UUO group, and AKF-PD significantly inhibited epithelial cells apoptosis. The expression of FADD, Apaf-1, and CHOP proteins was significantly upregulated in the UUO group and downregulated by enalapril and AKF-PD. In conclusion, AKF-PD improved renal interstitial fibrosis by inhibiting apoptosis of renal tubular epithelial cells in rats with UUO.


Asunto(s)
Apoptosis/efectos de los fármacos , Células Epiteliales/efectos de los fármacos , Enfermedades Renales/patología , Piridonas/farmacología , Obstrucción Ureteral/patología , Inhibidores de la Enzima Convertidora de Angiotensina/metabolismo , Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Animales , Factor Apoptótico 1 Activador de Proteasas/efectos de los fármacos , Factor Apoptótico 1 Activador de Proteasas/metabolismo , Nitrógeno de la Urea Sanguínea , Colágeno Tipo I/efectos de los fármacos , Colágeno Tipo I/metabolismo , Creatinina/sangre , Modelos Animales de Enfermedad , Enalapril/metabolismo , Enalapril/farmacología , Proteína de Dominio de Muerte Asociada a Fas/efectos de los fármacos , Proteína de Dominio de Muerte Asociada a Fas/metabolismo , Fibrosis , Masculino , Piridonas/metabolismo , Distribución Aleatoria , Ratas Sprague-Dawley , Factor de Transcripción CHOP/efectos de los fármacos , Factor de Transcripción CHOP/metabolismo
3.
Braz. j. med. biol. res ; 52(11): e8772, 2019. graf
Artículo en Inglés | LILACS | ID: biblio-1039259

RESUMEN

This study aimed to investigate the mechanism of fluorofenidone (AKF-PD) in treating renal interstitial fibrosis in rats with unilateral urinary obstruction (UUO). Thirty-two male Sprague-Dawley rats were randomly divided into sham, UUO, UUO + enalapril, and UUO + AKF-PD groups. All rats, except sham, underwent left urethral obstruction surgery to establish the animal model. Rats were sacrificed 14 days after surgery, and serum was collected for renal function examination. Kidneys were collected to observe pathological changes. Immunohistochemistry was performed to assess collagen I (Col I) protein expression, and terminal deoxynucleotidyl transferase-mediated nick end-labeling staining to observe the apoptosis of renal tubular epithelial cells. The expression of Fas-associated death domain (FADD), apoptotic protease activating factor-1 (Apaf-1), and C/EBP homologous protein (CHOP) proteins was evaluated by immunohistochemistry and western blot analysis. AKF-PD showed no significant effect on renal function in UUO rats. The pathological changes were alleviated significantly after enalapril or AKF-PD treatment, but with no significant differences between the two groups. Col I protein was overexpressed in the UUO group, which was inhibited by both enalapril and AKF-PD. The number of apoptotic renal tubular epithelial cells was much higher in the UUO group, and AKF-PD significantly inhibited epithelial cells apoptosis. The expression of FADD, Apaf-1, and CHOP proteins was significantly upregulated in the UUO group and downregulated by enalapril and AKF-PD. In conclusion, AKF-PD improved renal interstitial fibrosis by inhibiting apoptosis of renal tubular epithelial cells in rats with UUO.


Asunto(s)
Animales , Masculino , Piridonas/farmacología , Obstrucción Ureteral/patología , Apoptosis/efectos de los fármacos , Células Epiteliales/efectos de los fármacos , Enfermedades Renales/patología , Piridonas/metabolismo , Nitrógeno de la Urea Sanguínea , Fibrosis , Inhibidores de la Enzima Convertidora de Angiotensina/metabolismo , Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Enalapril/metabolismo , Enalapril/farmacología , Distribución Aleatoria , Ratas Sprague-Dawley , Creatinina/sangre , Colágeno Tipo I/efectos de los fármacos , Colágeno Tipo I/metabolismo , Modelos Animales de Enfermedad , Factor de Transcripción CHOP/efectos de los fármacos , Factor Apoptótico 1 Activador de Proteasas/efectos de los fármacos , Factor Apoptótico 1 Activador de Proteasas/metabolismo , Proteína de Dominio de Muerte Asociada a Fas/efectos de los fármacos , Proteína de Dominio de Muerte Asociada a Fas/metabolismo
4.
Psychopharmacology (Berl) ; 233(15-16): 2955-71, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-27259485

RESUMEN

RATIONALE: Fas-associated death domain (FADD) is an adaptor of death receptors that can also induce anti-apoptotic actions through its phosphorylated form (p-FADD). Activation of monoamine receptors, indirect targets of classic anti-depressant drugs (ADs), reduced FADD and increased p-FADD and p-FADD/FADD ratio in brain. OBJECTIVES: To ascertain whether ADs, which indirectly regulate monoamine receptors, modulate FADD protein forms to promote anti-apoptotic actions. METHODS: The effects of selected norepinephrine transporter (NET), serotonin transporter (SERT), monoamine oxidase (MAO) inhibitors, atypical ADs, and electroconvulsive shock (ECS) or behavioral procedures (forced swim test, FST) on FADD forms and pro-survival FADD-like interleukin-1ß-converting enzyme-inhibitory protein (FLIP-L) and phosphoprotein enriched in astrocytes of 15 kDa (p-PEA-15) contents were assessed in rat brain cortex by western blot analysis. RESULTS: Acute NET (e.g., nisoxetine) but not SERT (e.g., fluoxetine) inhibitors decreased cortical FADD (up to 37 %) and increased p-FADD/FADD ratio (up to 1.9-fold). Nisoxetine effects were prevented by α2-antagonist RX-821002, suggesting the involvement of presynaptic α2-autoreceptors. Immobility time in the FST correlated with increases of pro-apoptotic FADD and decreases of anti-apoptotic p-FADD. The MAO-A/B inhibitor phenelzine decreased FADD (up to 33 %) and increased p-FADD (up to 65 %) and p-FADD/FADD (up to 2.4-fold). Other MAO inhibitors (clorgyline, Ro 41-1049, rasagiline), atypical ADs (ketamine and mirtazapine), or ECS did not modulate cortical FADD. Chronic (14 days) desipramine and fluoxetine, but not phenelzine, increased p-FADD (up to 59 %), p-FADD/FADD ratio (up to 1.8-fold), and pro-survival p-PEA-15 (up to 46 %) in rat brain cortex. CONCLUSIONS: Multifunctional FADD protein, through an increased p-FADD/FADD ratio, could participate in the mechanisms of anti-apoptotic actions induced by ADs.


Asunto(s)
Antidepresivos/farmacología , Corteza Cerebral/efectos de los fármacos , Desipramina/farmacología , Proteína de Dominio de Muerte Asociada a Fas/efectos de los fármacos , Fluoxetina/farmacología , Antagonistas Adrenérgicos alfa/farmacología , Animales , Apoptosis , Autorreceptores/metabolismo , Western Blotting , Encéfalo/efectos de los fármacos , Proteína Reguladora de Apoptosis Similar a CASP8 y FADD , Corteza Cerebral/metabolismo , Clorgilina/farmacología , Electrochoque , Antagonistas de Aminoácidos Excitadores/farmacología , Proteína de Dominio de Muerte Asociada a Fas/metabolismo , Fluoxetina/análogos & derivados , Idazoxan/análogos & derivados , Idazoxan/farmacología , Indanos/farmacología , Ketamina/farmacología , Masculino , Mianserina/análogos & derivados , Mianserina/farmacología , Mirtazapina , Inhibidores de la Monoaminooxidasa/farmacología , Proteínas de Transporte de Noradrenalina a través de la Membrana Plasmática/antagonistas & inhibidores , Fenelzina/farmacología , Fosfoproteínas/efectos de los fármacos , Fosfoproteínas/metabolismo , Fosforilación/efectos de los fármacos , Proteínas de Unión al ARN/antagonistas & inhibidores , Ratas , Tiazoles/farmacología
5.
Toxicol Lett ; 190(2): 224-30, 2009 Oct 28.
Artículo en Inglés | MEDLINE | ID: mdl-19646514

RESUMEN

Perfluorononanoic acid (PFNA, C9), a synthetic perfluorinated chemical containing nine carbons, accumulates and is biomagnified through food webs. This compound has been detected in the serum of humans and wildlife and has the potential for reproductive interference. Few studies, however, have reported the effects of PFNA exposure on male reproduction. To determine this, male rats were orally dosed for 1, 3 and 5mg/kgday PFNA or with vehicle for 14 days. In the present study, serum testosterone levels were decreased, while estradiol levels were increased dramatically in rats receiving 5mg PFNA/kgday. Spermatogenic cells from rats that received 5mg PFNA/kgday exhibited apoptotic features including crescent chromatin condensation and chromatin margination. Flow cytometric analysis and TUNEL assays revealed a dose-dependent increase of apoptotic cell numbers. In addition, expression of Fas and Bax mRNA levels were upregulated significantly, and Bcl-2 mRNA levels were downregulated markedly in the 3 and 5mg/kgday groups. A dose-dependent increase in levels of active caspase-8 and no significant changes of active caspase-9 were observed. Our results indicate that PFNA exposure can lead to cell apoptosis in rat testis, and this apoptosis was probably associated with the Fas death receptor-dependent apoptotic pathway.


Asunto(s)
Apoptosis/efectos de los fármacos , Proteína de Dominio de Muerte Asociada a Fas/efectos de los fármacos , Proteína de Dominio de Muerte Asociada a Fas/fisiología , Ácidos Grasos/toxicidad , Transducción de Señal/efectos de los fármacos , Testículo/metabolismo , Animales , Proteínas Reguladoras de la Apoptosis/biosíntesis , Proteínas Reguladoras de la Apoptosis/genética , Western Blotting , Relación Dosis-Respuesta a Droga , Estradiol/metabolismo , Proteína de Dominio de Muerte Asociada a Fas/genética , Citometría de Flujo , Fluorocarburos , Expresión Génica/efectos de los fármacos , Masculino , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , Ratas , Ratas Sprague-Dawley , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Transducción de Señal/genética , Testículo/citología , Testículo/efectos de los fármacos , Testosterona/metabolismo
6.
J Neurooncol ; 93(3): 303-18, 2009 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-19148581

RESUMEN

OBJECT: Apoptosis, a key cellular response to therapeutic agents is often inactivated in tumor cells. In this study, we evaluated the expression of the tumor necrosis family of death receptors, DR4 and DR5, in medulloblastoma tumor samples and cell lines to determine if epigenetic modulation of gene expression could sensitize tumor cell lines to TRAIL-mediated apoptosis. METHODS: Human medulloblastoma samples and cell lines were analyzed for DR4 and DR5 expression by quantitative PCR and immunofluorescence assays. Cell lines with downregulated expression of one or both genes were treated with the histone deacetylase inhibitor, MS-275, and the expression of DR4 and DR5 measured by quantitative PCR, Western blotting, flow cytometry and chromatin immunoprecipitation assays. Induction of apoptosis in the presence of MS-275 was evaluated by TUNEL assay and its ability to augment TRAIL-mediated cytotoxicity was determined by MTT assays, Western blotting and flow cytometry. RESULTS: Compared to normal cerebellum, DR4, but not DR5 expression was consistently downregulated in medulloblastoma tumor samples and in Daoy and D283 cell lines. Interestingly, MS-275 decreased cell growth and induced apoptosis in Daoy and D283 cells. In Daoy cells, this coincided with increased histone H3 and H4 acetylation at the DR4 promoter and enhanced DR4 gene and protein expression as well as elevated Caspase-8 activity. The involvement of DR4 in the cellular response to MS-275 was further confirmed by the observation that knockdown of DR4 and FADD abrogated apoptosis. Further, addition of TRAIL to MS-275 treated cells resulted in an enhancement of apoptosis, suggesting that the upregulated death receptors were functional. CONCLUSION: Our study provides an understanding of the role of DR4 in apoptosis of medulloblastoma cell lines and suggests a potential contribution of aberrant histone deacetylation to the resistance of medulloblastoma cells to therapeutic death.


Asunto(s)
Apoptosis/fisiología , Neoplasias Cerebelosas/metabolismo , Meduloblastoma/metabolismo , Receptores del Ligando Inductor de Apoptosis Relacionado con TNF/metabolismo , Ligando Inductor de Apoptosis Relacionado con TNF/metabolismo , Apoptosis/efectos de los fármacos , Benzamidas/farmacología , Western Blotting , Caspasa 8/metabolismo , Línea Celular Tumoral , Neoplasias Cerebelosas/genética , Inhibidores Enzimáticos/farmacología , Proteína de Dominio de Muerte Asociada a Fas/efectos de los fármacos , Proteína de Dominio de Muerte Asociada a Fas/metabolismo , Citometría de Flujo , Técnica del Anticuerpo Fluorescente , Expresión Génica , Inhibidores de Histona Desacetilasas , Humanos , Inmunoprecipitación , Etiquetado Corte-Fin in Situ , Meduloblastoma/genética , Piridinas/farmacología , Receptores del Ligando Inductor de Apoptosis Relacionado con TNF/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Ligando Inductor de Apoptosis Relacionado con TNF/genética , Ligando Inductor de Apoptosis Relacionado con TNF/farmacología
7.
Arch Inst Pasteur Tunis ; 86(1-4): 15-25, 2009.
Artículo en Francés | MEDLINE | ID: mdl-20707217

RESUMEN

Bleomycins are a family of glycopeptides isolated from streptomyces verticillus and exhibiting antibiotic properties. They are commonly included in chemotherapy regimens used to treat patients with Hodgkin's or non Hodgkin's malignant lymphoma, squamous-cell carcinoma or germ-cell tumor. The chemical structure and action mode of bleomycin have been extensively studied, in contrast, the molecular mechanisms of the cytotoxic effects of bleomycin, in vivo, remain poorly understood. Recently, the apoptotics signaling pathway induce by bleomycin was the object of study, of many groups. In this sense, some studies suggested that bleomycin induce in some cells different apoptotic pathway in dose and time depending manner. The sensibility or the resistance to apoptosis induced by bleomycin may explain the sensibility or the resistance of tumor cells to bleomycin. The aim of this review was to describe the machinery of apoptosis induced by bleomycin in tumor cells.


Asunto(s)
Antibióticos Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Bleomicina/farmacología , Antibióticos Antineoplásicos/química , Antibióticos Antineoplásicos/uso terapéutico , Apoptosis/fisiología , Bleomicina/química , Bleomicina/uso terapéutico , Carcinoma de Células Escamosas/tratamiento farmacológico , Caspasas/efectos de los fármacos , Caspasas/fisiología , Relación Dosis-Respuesta a Droga , Resistencia a Antineoplásicos/efectos de los fármacos , Resistencia a Antineoplásicos/fisiología , Proteína de Dominio de Muerte Asociada a Fas/efectos de los fármacos , Proteína de Dominio de Muerte Asociada a Fas/fisiología , Radicales Libres/efectos adversos , Humanos , Linfoma no Hodgkin/tratamiento farmacológico , Mitocondrias/efectos de los fármacos , Mitocondrias/fisiología , Quinasas de Proteína Quinasa Activadas por Mitógenos/efectos de los fármacos , Quinasas de Proteína Quinasa Activadas por Mitógenos/fisiología , Modelos Químicos , Neoplasias de Células Germinales y Embrionarias/tratamiento farmacológico , Transducción de Señal/efectos de los fármacos , Transducción de Señal/fisiología
8.
Nat Rev Drug Discov ; 7(12): 1001-12, 2008 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-18989337

RESUMEN

Each day, the human body eliminates billions of unwanted cells by apoptotic suicide. Apoptosis provides an important barrier against cancer; however, specific mutations enable some tumour cells to escape apoptotic death and become more malignant. Two signalling pathways initiate apoptosis: one acts through intracellular Bcl-2 proteins, the other through cell-surface pro-apoptotic receptors. New molecular insights have inspired the development of pro-apoptotic receptor agonists (PARAs), including the recombinant human protein apoptosis ligand 2/TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) and agonistic monoclonal antibodies to its signalling receptors. Acting alone, or in concert with other agents, PARAs may overcome key apoptosis blocks and direct cancer cells to self-destruct.


Asunto(s)
Antineoplásicos/uso terapéutico , Proteínas Reguladoras de la Apoptosis/efectos de los fármacos , Apoptosis/efectos de los fármacos , Neoplasias/tratamiento farmacológico , Neoplasias/patología , Transformación Celular Neoplásica/efectos de los fármacos , ADN de Neoplasias/efectos de los fármacos , ADN de Neoplasias/genética , Diseño de Fármacos , Proteína de Dominio de Muerte Asociada a Fas/efectos de los fármacos , Proteína de Dominio de Muerte Asociada a Fas/fisiología , Humanos , Neoplasias/genética , Receptores de Muerte Celular/efectos de los fármacos , Receptores de Muerte Celular/fisiología , Transducción de Señal/fisiología
9.
Apoptosis ; 13(8): 983-92, 2008 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-18543108

RESUMEN

FADD/MORT1 (The adaptor protein of Fas Associate Death Domain/Mediator of Receptor Induced Toxicity) is essential for signal transduction of death receptor signaling. We have previously shown that FADD is significantly up-regulated in TNFalpha/ActD induced apoptosis. Over-expression of FADD also induces death of lung cancer cells and primary hepatocytes. We hypothesize that the increase in detectable FADD levels require the proximal steps in apoptotic signaling and speculated that FADD would be redistributed in cells destined to undergo apoptosis. We show that monomeric non-phosphorylated FADD is up-regulated in hepatocytes treated with TNFalpha/ActD and that it accumulates in the cytoplasm. Nuclear phosphorylated FADD decreases with TNFalpha/ActD treatment. Dimeric FADD in the cytoplasm remains constant with TNFalpha/ActD. The change in FADD levels and distribution was dependent on caspase-3, caspase-8 activity and the presence of BID. Thus, changes in FADD levels and distribution are downstream of caspase activation and mitochondria changes that are initiated by the formation of the DISC complex. Changes in FADD levels and distribution may represent a novel feed-forward mechanism to propagate apoptosis signaling in hepatocytes.


Asunto(s)
Apoptosis/fisiología , Proteína Proapoptótica que Interacciona Mediante Dominios BH3/metabolismo , Caspasas/metabolismo , Proteína de Dominio de Muerte Asociada a Fas/metabolismo , Hepatocitos/metabolismo , Factor de Necrosis Tumoral alfa/metabolismo , Transporte Activo de Núcleo Celular/efectos de los fármacos , Transporte Activo de Núcleo Celular/fisiología , Animales , Apoptosis/efectos de los fármacos , Proteína Proapoptótica que Interacciona Mediante Dominios BH3/efectos de los fármacos , Caspasa 3/efectos de los fármacos , Caspasa 3/metabolismo , Caspasa 8/efectos de los fármacos , Caspasa 8/metabolismo , Caspasas/efectos de los fármacos , Citoplasma/efectos de los fármacos , Citoplasma/metabolismo , Dactinomicina/farmacología , Proteínas Adaptadoras de Señalización del Receptor del Dominio de Muerte/efectos de los fármacos , Proteínas Adaptadoras de Señalización del Receptor del Dominio de Muerte/metabolismo , Proteína de Dominio de Muerte Asociada a Fas/efectos de los fármacos , Hepatocitos/efectos de los fármacos , Humanos , Masculino , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Potencial de la Membrana Mitocondrial/fisiología , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Fosforilación/efectos de los fármacos , Transducción de Señal/efectos de los fármacos , Transducción de Señal/fisiología , Factor de Necrosis Tumoral alfa/efectos de los fármacos , Regulación hacia Arriba/efectos de los fármacos , Regulación hacia Arriba/fisiología
10.
J Neurochem ; 106(1): 281-98, 2008 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-18373618

RESUMEN

Localized tumor necrosis factor-alpha (TNFalpha) elevation has diverse effects in brain injury often attributed to signaling via TNFp55 or TNFp75 receptors. Both dentate granule cells and CA pyramidal cells express TNF receptors (TNFR) at low levels in a punctate pattern. Using a model to induce selective death of dentate granule cells (trimethyltin; 2 mg/kg, i.p.), neuronal apoptosis [terminal deoxynucleotidyl transferase-mediated dUTP-biotin in situ end labeling, active caspase 3 (AC3)] was accompanied by amoeboid microglia and elevated TNFalpha mRNA levels. TNFp55R (55 kDa type-1 TNFR) and TNFp75R (75 kDa type-2 TNFR) immunoreactivity in AC3(+) neurons displayed a pattern suggestive of receptor internalization and a temporal sequence of expression of TNFp55R followed by TNFp75R associated with the progression of apoptosis. A distinct ramified microglia response occurred around CA1 neurons and healthy dentate neurons that displayed an increase in the normal punctate pattern of TNFRs. Neuronal damage was decreased with i.c.v. injection of TNFalpha antibody and in TNFp55R-/-p75R-/- mice that showed higher constitutive mRNA levels for interleukin (IL-1alpha), macrophage inflammatory protein 1-alpha (MIP-1alpha), TNFalpha, transforming growth factor beta1, Fas, and TNFRSF6-assoicated via death domain (FADD). TNFp75R-/- mice showed exacerbated injury and elevated mRNA levels for IL-1alpha, MIP-1alpha, and TNFalpha. In TNFp55R-/- mice, constitutive mRNA levels for TNFalpha, IL-6, caspase 8, FADD, and Fas-associated phosphatase were higher; IL-1alpha, MIP-1alpha, and transforming growth factor beta1 lower. The mice displayed exacerbated neuronal death, delayed microglia response, increased FADD and TNFp75R mRNA levels, and co-expression of TNFp75R in AC3(+) neurons. The data demonstrate TNFR-mediated apoptotic death of dentate granule neurons utilizing both TNFRs and suggest a TNFp75R-mediated apoptosis in the absence of normal TNFp55R activity.


Asunto(s)
Apoptosis/inmunología , Giro Dentado/metabolismo , Degeneración Nerviosa/metabolismo , Neuronas/metabolismo , Receptores de Factor de Crecimiento Nervioso/metabolismo , Receptores Tipo I de Factores de Necrosis Tumoral/metabolismo , Receptores del Factor de Necrosis Tumoral/metabolismo , Animales , Apoptosis/efectos de los fármacos , Proteínas Reguladoras de la Apoptosis/efectos de los fármacos , Proteínas Reguladoras de la Apoptosis/genética , Proteínas Reguladoras de la Apoptosis/metabolismo , Citocinas/efectos de los fármacos , Citocinas/genética , Citocinas/metabolismo , Giro Dentado/inmunología , Giro Dentado/patología , Endocitosis/efectos de los fármacos , Endocitosis/fisiología , Proteína de Dominio de Muerte Asociada a Fas/efectos de los fármacos , Proteína de Dominio de Muerte Asociada a Fas/genética , Proteína de Dominio de Muerte Asociada a Fas/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Microglía/efectos de los fármacos , Microglía/inmunología , Degeneración Nerviosa/inducido químicamente , Degeneración Nerviosa/inmunología , Neuronas/efectos de los fármacos , Neuronas/inmunología , Neurotoxinas/toxicidad , Receptores de Factor de Crecimiento Nervioso/efectos de los fármacos , Receptores de Factor de Crecimiento Nervioso/genética , Receptores del Factor de Necrosis Tumoral/efectos de los fármacos , Receptores del Factor de Necrosis Tumoral/genética , Receptores Tipo I de Factores de Necrosis Tumoral/efectos de los fármacos , Receptores Tipo I de Factores de Necrosis Tumoral/genética , Compuestos de Trimetilestaño/toxicidad
11.
Apoptosis ; 13(4): 509-22, 2008 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-18347986

RESUMEN

Human COLO 205 colon adenocarcinoma cells are immune to extrinsic apoptosis induced by immunomodulatory cytokines. Among the antiapoptotic mechanisms responsible for the immune escape, the overexpression of the cFLIP protein seems to be critical. cFLIP appears to inhibit the TNF-alpha-induced death receptor signal. The application of the metabolic inhibitor bisindolylmaleimide IX (Bis-IX), known as a potent PKC repressor, sensitized COLO 205 cells to TNF-alpha-mediated apoptosis. The Western-blot analysis revealed that the susceptibility of human COLO 205 cells to apoptogenic stimuli resulted from time-dependent reduction in cFLIP(L) and TRADD protein levels. At the same time, the level of FADD protein was up-regulated. Additionally, the combined TNF-alpha and Bis-IX treatment caused cleavages of Bid and procaspase-9, as well as cytochrome c release. Thus, the evidence of this study indicates that Bis-IX facilitates the death receptor signal mediated by TNF-R1. Moreover, Bis-IX alone initiated intrinsic apoptosis, which could be abolished by Bcl-2 delivery. It heralds the involvement of mitochondria in caspase-8-independent intrinsic apoptosis. In turn, the treatment with bisindolylmaleimide III (Bis-III) did not assist TNF-alpha-dependent apoptosis.


Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Apoptosis/efectos de los fármacos , Neoplasias del Colon/tratamiento farmacológico , Indoles/uso terapéutico , Maleimidas/uso terapéutico , Factor de Necrosis Tumoral alfa/farmacología , Adenocarcinoma/patología , Proteína Reguladora de Apoptosis Similar a CASP8 y FADD/efectos de los fármacos , Proteína Reguladora de Apoptosis Similar a CASP8 y FADD/metabolismo , Caspasa 9/efectos de los fármacos , Caspasa 9/metabolismo , Línea Celular Tumoral , Neoplasias del Colon/patología , Resistencia a Antineoplásicos , Sinergismo Farmacológico , Proteína de Dominio de Muerte Asociada a Fas/efectos de los fármacos , Humanos , Indoles/farmacología , Maleimidas/farmacología , Proteína Quinasa C/antagonistas & inhibidores , Estaurosporina/farmacología , Proteína de Dominio de Muerte Asociada a Receptor de TNF/efectos de los fármacos , Regulación hacia Arriba
12.
Blood ; 109(2): 711-9, 2007 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-17003375

RESUMEN

Multiple myeloma (MM) is an incurable B-cell malignancy, requiring new therapeutic strategies. We have found that synthetic alkyl-lysophospholipids (ALPs) edelfosine and perifosine induced apoptosis in MM cell lines and patient MM cells, whereas normal B and T lymphocytes were spared. ALPs induced recruitment of Fas/CD95 death receptor, Fas-associated death domain-containing protein, and procaspase-8 into lipid rafts, leading to the formation of the death-inducing signaling complex (DISC) and apoptosis. TNF-related apoptosis-inducing ligand receptor-1/death receptor 4 (TRAIL-R1/DR4) and TRAIL-R2/DR5, as well as Bid, were also recruited into lipid rafts, linking death receptor and mitochondrial signaling pathways. ALPs induced mitochondrial cytochrome c release. Bcl-X(L) overexpression prevented cytochrome c release and apoptosis. A Fas/CD95-deficient MM subline expressing DR4 and DR5 was resistant to edelfosine. Fas/CD95 retrovirus transduction bestowed edelfosine sensitivity in these cells. A Fas/CD95 mutant lacking part of the intracellular domain was ineffective. Lipid raft disruption prevented ALP-induced Fas/CD95 clustering, DISC formation, and apoptosis. ALP-induced apoptosis was Fas/CD95 ligand (FasL/CD95L) independent. ALP-induced recruitment of death receptors in lipid rafts potentiated MM cell killing by FasL/CD95L and TRAIL. These data uncover a novel lipid raft-mediated therapy in MM involving concentration of death receptors in membrane rafts, with Fas/CD95 playing a major role in ALP-mediated apoptosis.


Asunto(s)
Apoptosis/efectos de los fármacos , Caspasa 8/metabolismo , Proteína de Dominio de Muerte Asociada a Fas/metabolismo , Microdominios de Membrana/metabolismo , Mieloma Múltiple/metabolismo , Éteres Fosfolípidos/farmacología , Fosforilcolina/análogos & derivados , Caspasa 8/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Proteína de Dominio de Muerte Asociada a Fas/efectos de los fármacos , Humanos , Mieloma Múltiple/tratamiento farmacológico , Mieloma Múltiple/patología , Éteres Fosfolípidos/síntesis química , Éteres Fosfolípidos/química , Fosforilcolina/síntesis química , Fosforilcolina/química , Fosforilcolina/farmacología , Transducción de Señal/efectos de los fármacos , Relación Estructura-Actividad , Receptor fas/efectos de los fármacos , Receptor fas/metabolismo
13.
Neuropsychopharmacology ; 32(2): 399-411, 2007 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-16482086

RESUMEN

This study was designed to assess the effects of opiate treatment on the expression of Fas-associated protein with death domain (FADD) in the rat brain. FADD is involved in the transmission of Fas-death signals that have been suggested to contribute to the development of opiate tolerance and addiction. Acute treatments with high doses of sufentanil and morphine (mu-agonists), SNC-80 (delta-agonist), and U50488H (kappa-agonist) induced significant decreases (30-60%) in FADD immunodensity in the cerebral cortex, through specific opioid receptor mechanisms (effects antagonized by naloxone, naltrindole, or nor-binaltorphimine). The cannabinoid CB1 receptor agonist WIN 55,212-2 did not alter FADD content in the brain. Chronic (5 days) morphine (10-100 mg/kg), SNC-80 (10 mg/kg), or U50488H (10 mg/kg) was associated with the induction of tachyphylaxis to the acute effects. In morphine- and SNC-80-tolerant rats, antagonist-precipitated (2 h) or spontaneous withdrawal (24-48 h) induced a new and sustained inhibition of FADD (13-50%). None of these treatments altered the densities of caspases 8/3 (including the active cleaved forms) in the brain. Pretreatment of rats with SL 327 (a selective MEK1/2 inhibitor that blocks ERK activation) fully prevented the reduction of FADD content induced by SNC-80 in the cerebral cortex (43%) and corpus striatum (29%), demonstrating the direct involvement of ERK1/2 signaling in the regulation of FADD by the opiate agonist. The results indicate that mu- and delta-opioid receptors have a prominent role in the modulation of FADD (opposite to that of Fas) shortly after initiating treatment. Opiate drugs (and specifically the delta-agonists) could promote survival signals in the brain through inhibition of FADD, which in turn is dependent on the activation of the antiapoptotic ERK1/2 signaling pathway.


Asunto(s)
Analgésicos Opioides/farmacología , Encéfalo/efectos de los fármacos , Caspasas Efectoras/efectos de los fármacos , Quinasas MAP Reguladas por Señal Extracelular/efectos de los fármacos , Proteína de Dominio de Muerte Asociada a Fas/efectos de los fármacos , Trastornos Relacionados con Opioides/metabolismo , Animales , Encéfalo/metabolismo , Encéfalo/fisiopatología , Caspasas Efectoras/metabolismo , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/metabolismo , Corteza Cerebral/fisiopatología , Cuerpo Estriado/efectos de los fármacos , Cuerpo Estriado/metabolismo , Cuerpo Estriado/fisiopatología , Modelos Animales de Enfermedad , Tolerancia a Medicamentos/fisiología , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Proteína de Dominio de Muerte Asociada a Fas/metabolismo , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Sistema de Señalización de MAP Quinasas/fisiología , Masculino , Antagonistas de Narcóticos/farmacología , Trastornos Relacionados con Opioides/fisiopatología , Ratas , Ratas Sprague-Dawley , Receptores Opioides delta/agonistas , Receptores Opioides delta/metabolismo , Receptores Opioides kappa/agonistas , Receptores Opioides kappa/metabolismo , Receptores Opioides mu/agonistas , Receptores Opioides mu/metabolismo , Síndrome de Abstinencia a Sustancias/metabolismo , Síndrome de Abstinencia a Sustancias/fisiopatología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA